The Del1 deposition domain can immobilize 3α-hydroxysteroid dehydrogenase in the extracellular matrix without interfering with enzymatic activity by Hidai, Chiaki et al.
ORIGINAL PAPER
The Del1 deposition domain can immobilize 3a-hydroxysteroid
dehydrogenase in the extracellular matrix without interfering
with enzymatic activity
Chiaki Hidai Æ Hisataka Kitano Æ Shinichiro Kokubun
Received: 14 June 2008/Accepted: 29 October 2008/Published online: 19 November 2008
 The Author(s) 2008. This article is published with open access at Springerlink.com
Abstract Developing methods that result in targeting of
therapeutic molecules in gene therapies to target tissues has
importance, as targeting can increase efﬁcacy and decrease
off target-side-effects. Work from my laboratory previ-
ously showed that the extracellular matrix protein Del1 is
organized in the extracellular matrix (ECM) via the Del1
deposition domain (DDD). In this work, a fusion protein
with DDD was made to assay the ability to immobilize an
enzyme without disrupting enzymatic function. A prostatic
cancer-derived cell line LNCap that grows in an androgen-
dependent manner was used with 3a-hydroxysteroid
dehydrogenase (3 aHD), which catalyzes dihydrotestos-
terone (DHT). Plasmids encoding a 3aHD:DDD fusion
were generated and transfected into cultured cells. The
effects of 3aHD immobilized in the ECM by the DDD
were evaluated by monitoring growth of LNCap cells and
DHT concentrations. It was demonstrated that the DDD
could immobilize an enzyme in the ECM without inter-
fering with function.
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Introduction
Mouse Del1 is an ECM protein secreted by embryonic
endothelial cells and hypertrophic chondrocytes [1]. Del1
consists of ﬁve domains: three epidermal growth factor
(EGF) repeat domains (E1, E2, E3) and two Discoidin
domains (C1, C2). Work from my laboratory recently
showed that the C-termini of the C1 domains are essential
for organization of Del1 into the ECM and that both the E3
repeat domain and the N-terminus of the C1 domain play
supportive roles in organization into the ECM [2]. We
termed this portion of the C1 domain the Del1 deposition
domain (DDD). Fusion proteins that include the DDD and
an alkaline phosphatase protein as a marker accumulate in
the ECM without interfering with enzyme activity of the
alkaline phosphatase.
In some therapeutic treatments, localization of bioactive
molecules speciﬁcally to the target tissue(s) increases the
concentration of bioactive molecules in the target cells.
This results in higher efﬁciency of treatment and because
the concentration of the bioactive molecules in non-target
tissues is minimized, this can also result in a lower inci-
dence of treatment side effects. The purpose of this study is
to ask if addition of DDD to an enzyme can result in
localization of that enzyme to the ECM without affecting
activity of the enzyme. Because the space between a cell
and the ECM is not a simple vacancy, it is important to ask
if a fusion protein derived from an enzyme is functional in
the microenvironment of the ECM.
To address this, I designed a cell-based system in
which it is possible to readily monitor both an enzyme
and the enzymatic products it produces. LNCap cells are
prostatic cancer-derived cells that grow in an androgen-
dependent manner and these cells were used as a model
target cell in this study [3, 4]. DDD was used to
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which intracellularly catalyzes the conversion of alde-
hydes and ketones to alcohols, and converts DHT to 5a-
androstane-3a-, 17b-diol physiologically [5]. In this study,
recombinant 3aHD proteins were secreted extracellularly
as a result of addition of a signal sequence at the N-
terminus of the recombinant protein (Fig. 1a, b). The
addition of a DDD to the 3aHD protein successfully
localized the protein to the ECM. Moreover, the 3aHD in
ECM was biochemically active and suppressed growth of
LNCap cells.
Methods
Cell culture and evaluation of cell growth
LNCap (CRL-1740) and Cos-7 (CRL-1651) cells were
purchased from ATCC and grown in a-minimum essen-
tial medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (Invitrogen) at 37Ci na n
atmosphere containing 5% CO2. To evaluate dependency
of cell growth on DHT, 50% conﬂuent LNCap cells were
prepared in a 24 well plate with 300 ll of a serum free
medium, VP-SFM (Invitrogen) and different concentra-
tions of DHT (Wako, Osaka, Japan) were added. After
4 days of culture, 30 ll of WST-1 (Takara, Outs, Japan)
were added to the medium, incubated for 1 hour, and the
absorbance at 405 nm was measured. The experiment
was repeated three times and representative data are
shown.
DNA constructs
First, a synthetic oligonucleotide encoding the signal pep-
tide from Del1 (MKHLVAAWLLVGLSLGVPQFGKGDI)
was obtained and cloned into pcDNA3D (Invitrogen)
resulting in pcDNA3S. Next, a cDNA fragment encoding
the human 3aHD gene (AB178898) was ampliﬁed by
reverse transcriptase-PCR (RT-PCR) using the forward
primer, 50-AAGAATTCATGAACTCCAAATGTCATTG
TGTCAT and the reverse primer 50-AAGATATCGT
ATTCATCCAAAAATGGCCAATTAG. The ampliﬁed
fragment was cloned into the 30 end of the signal peptide,
resulting in p3aHD (Fig. 1a). Finally, a fragment encoding
the DDD (amino acids 122–316 of Del1) was ampliﬁed
with the forward primer 50-AAGATATCTGTGAAG
CTGAGCCTTGCAGAAAT and the reverse primer 50-A
ACTCGAGCATGTCCATGTTGAGTGTTCTGAA. This
was cloned into the 30 end of the 3aHD gene, resulting in
the plasmid p3aHD:DDD (Fig. 1a). The recombinant pro-
teins expressed by these constructs also had a V5 epitope
tag at their C terminal ends.
Immunoblotting
ECM samples for immunoblotting analysis were prepared
according to Hidai et al. [2]. Brieﬂy, Cos-7 cells in six-well
plate were transfected with pcDNA3S, p3aHD or
p3aHD:DDD using Lipofectamine 2000 (Invitrogen).
After 96 h of culture, conditioned medium was harvested.
Then, cells were induced to detach by treatment of EDTA
Fig. 1 A schematics for experiments. a DNA constructs generated
for transfection experiments. Following CMV promoter sequences
(Pcmv), cDNA of signal peptide (SP), cDNA of 3aHD gene
(3alphaHD) and cDNA of DDD (DDD) were inserted into pcDNA3D.
b A schematic cartoon of transfection experiments. A recombinant
protein of 3aHD with DDD is represented by an ellipsoid (3aHD)
with a rectangle (DDD). Filled squares and ﬁlled triangles indicate
DHT and catalyzed DHT, respectively. A zigzag line indicates ECM
570 Bioprocess Biosyst Eng (2009) 32:569–573
123and the remaining ECM was collected with a scraper. The
conditioned medium, cells, and ECM were ﬁxed with 10%
trichloracetic acid (Wako). The protein samples were
separated by SDS-PAGE and transferred to a PVDF
membrane (ATTO, Tokyo, Japan). The membrane was
incubated with anti-V5 antibody (Invitrogen), followed by
incubation with a horseradish peroxidase-conjugated sec-
ondary antibody, and immunoreactive proteins were
detected using the ECL Advance Western Blotting Detec-
tion Kit (Amersham, Piscataway, NJ).
Evaluation of the effects of exogenous 3aHD
LNCap cells were plated to 50% conﬂuency in a 24-well
dish and transfected with 1 lg of pcDNA3S, p3aHD, or
p3aHD:DDD using Lipofectamine2000. To test if an
excess of p3aHD was introduced, cell growth was moni-
tored after introduction of various amount of p3aHD. To
monitor transfection efﬁciency, 0.1 lg of cDNA for the
LacZ gene was co-transfected with each test construct.
Expression of LacZ gene was monitored by measuring b-
galactosidase enzyme activity using an assay system
(Promega, Madison, WI). Cell number was evaluated with
WST-1. The values obtained in samples transected with the
control plasmid, pcDNA3S, were normalized to 1. The
experiment was repeated three times and representative
data are shown.
Assays of conditioned ECM
ECM conditioned with 3aHD was prepared according to
Hidai et al. [2]. Brieﬂy, Cos-7 cells were cultured in a 24-
well dish and transfected with 1 lg of pcDNA3S, p3aHD,
or p3aHD:DDD using Lipofectamine2000. To standardize
transfection efﬁciency, 0.1 lgo fLacZ cDNA were co-
transfected. Four days later, the cells were washed with
phosphate buffered saline (PBS) and incubated in PBS
containing 10 mM EDTA and a protease inhibitor cocktail
(PIERCE, Rockford, IL) for 12 h at 48C. Next, cells were
harvested by vigorous pipetting, collected by centrifuga-
tion, resuspended in 100 ll of tris buffered saline (TBS),
and lysed by sonication. b-Galactosidase activity of the
cell lysates was then assayed. Next, 1 9 10
4 LNCap cells
were plated on the conditioned ECM, cultured for seven
days, and evaluated with WST-1. To ask if exogenous
DHT could rescue the growth of LNCap cells, various
amounts of DHT (Wako) were added to the medium. The
values obtained for samples transfected with the control
plasmid, pcDNA3S, were normalized to 1. The experiment
was repeated three times and representative data are
shown.
Measurement of dihydrotestosterone levels
ECM conditioned with 3aHD was prepared as described
above. Serum obtained from a male volunteer as approved
by Nihon University ethics committee was incubated with
conditioned ECM in the presence of a protease inhibitor
cocktail (PIERCE) for 96 h. The concentration of dihy-
drotestosterone in the serum was measured using the
Dihydrotestosterone ELISA kit (IBL, Hamburg, Germany)
according to the manufacture’s protocol. The values
obtained for samples transfected with the control plasmid,
pcDNA3S, were normalized to 1. The experiment was
repeated three times and representative data are shown.
Statistical analysis
Results were expressed as mean ± SEM. Dunn’s tests or a
Wilcoxon’s test were performed, and statistical signiﬁ-
cance was set at P\0.01.
Results and discussion
To conﬁrm characteristics of LNCap cells, the cells were
cultured in serum-free medium with various concentrations
of DHT. As previously reported [3, 4], growth of LNCap
cells was dose-dependently accelerated by addition of
exogenous DHT (Fig. 2a). Next, the distribution of
recombinant proteins in cells, ECM and medium was
examined. Cells transfected with the control plasmid
pcDNA3S, which encodes only a signal peptide (too small
to be detected by SDS-PAGE as shown in Fig. 2b), were
used as a negative control. The expected sizes of the
recombinant proteins encoded by p3aHD and p3aHD:DDD
were 43 kDa and 65 kDa, respectively (Fig. 2b). The
recombinant protein encoded by p3aHD was not detected in
ECM samples but was detected in conditioned medium and
in cells. The recombinant protein encoded by p3aHD:DDD
was localized to the ECM as expected for a DDD-con-
taining polypeptide. The results also show that the total
amount of 3aHD:DDD present in the culture medium was
greater than the total amount found in the ECM. However,
considering that the volume of medium was much larger
than the volume of ECM tested, the concentration of
3aHD:DDD was much higher in ECM than in medium.
Thus, it appears that the recombinant protein was concen-
trated in the ECM by the presence of the DDD.
To ask if recombinant proteins with 3aHD affect growth
of LNCap cells, plasmids encoding various 3aHD-derived
constructs were transfected into LNCap cells. Transfection
with p3aHD or p3aHD:DDD resulted in reduction of cell
growth at day 6 (Fig. 3a). To check that transfection efﬁ-
ciency did not vary grossly, transfection efﬁciency was
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transfection with a LacZ construct. Transfection of
p3aHD:DDD seemed to be more effective than that of
p3aHD (Fig. 3a). In this study, it was unfortunately
impossible to standardize protein levels. Strictly speaking,
our results cannot address if DDD improves the efﬁciency
or effects of an enzyme by concentrating it in the ECM, as
would be relevant to therapeutics [6]. The question may be
resolved in an in vivo study, wherein not only the distri-
bution but also the effects and side effects of the
recombinant proteins could be evaluated.
To determine if there is a dose-dependent relationship
between cell growth and the amount of p3aHD DNA
transfected into cells, the effect of transfection with dif-
ferent amounts of p3aHD DNA was tested (Fig. 3b). The
effect on cell growth was dependent on the amount of
p3aHD added, suggesting that suppression of cell growth
was not due to experimental procedures but instead, is the
result of 3aHD-speciﬁc effects.
DHT may be catabolized in cells transfected with the
3aHD construct; thus, I next assayed if a growth suppres-
sion effect is induced by ECM conditioned with
p3aHD:DDD (Fig. 4a). To again check that the transfec-
tion efﬁciency did not vary grossly, transfection efﬁciency
was monitored by assaying b-galactosidase activity.
Growth of cells on ECM conditioned by cells transfected
with p3aHD was not different from growth on control
ECM. However, ECM conditioned by cells transfected
with p3aHD:DDD signiﬁcantly suppressed the growth of
otherwise untreated LNCap cells.
On explanation for the effect observed in this work is
that the presence of 3aHD in the ECM decreases the
concentration of DHT in serum. To test this, serum was
incubated with conditioned ECM and the concentration of
DHT was measured in treated and untreated samples
(Fig. 4b). After 96 h, the concentration of DHT in serum
incubated with ECM conditioned with p3aHD:DDD had
signiﬁcantly decreased.
To conﬁrm that the p3aHD:DDD suppresses the growth
of LNCap cells via a decrease of DHT in medium, the
ability of exogenously added DHT to reverse the effect was
assayed (Fig. 4c). Administration of exogenous DHT was
Fig. 2 A cell-based readout of enzymatic activity. a Growth
dependence of LNCap cells on DHT. The results represent mean ± -
SEM (n = 6). b Immunoblotting analysis reveals expression of
recombinant proteins in cultured medium (Medi), cells, and ECM
Fig. 3 Exogenous expression of 3aHD in LNCap cells affects cell
growth. a Growth of LNCap cells was evaluated after transfection
with the plasmids p3aHD or p3aHD:DDD. A gene encoding b-
galactosidase (b-gal) was co-transfected as a control and b-gal
activity was used as a measure of transfection efﬁciency. b Growth of
LNCap cells was evaluated after introduction of different amounts of
the p3aHD construct. Open bars LNCap cell numbers; closed bars b-
gal activity as a measure of transfection efﬁciency. The results
represent mean ± SEM (n = 6). **P\0.01
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of p3aHD:DDD.
In a previous study, it was found that alkaline phos-
phatase protein was efﬁciently deposited in the ECM in
vitro and in vivo [2]. The present study suggests that DDD
can ﬁx enzymes in the ECM in a functional state, sug-
gesting some biomedical applications for DDD fusion
proteins. In cytotherapy, for example, cells could be pre-
engineered with a cDNA encoding a speciﬁc DDD fusion
protein. Because DDD has been reported to be effective for
targeting to ECMs from various kinds of cells, one can
predict that cell choice may be dictated solely according to
need and that the ECM conditioned by the cells can then
serve as a source of active enzyme.
Similarly, a system involving a DDD fusion protein
under the control of a tissue-speciﬁc promoter could efﬁ-
ciently localize an exogenous protein useful in gene
therapy and thus presumably, target the effects of that
enzyme to a speciﬁc cell type and/or location. This has
promise for generating regions of high local concentration
while at the same time, resulting in only a low systemic
concentration of the therapeutic proteins by virtue of their
deposition in ECM. To apply the idea further, one can
imagine that chemicals capable of being activated by an
enzyme may then by activated in a limited region, such as
in a speciﬁc target tissue or cell type, via expression of an
ECM-anchored version of the activating enzyme.
In addition to enzymes, some ligands, such as the FAS
ligand, might be used as partners of DDD and the system
adapted to other applications [7]. That is, the presence of a
cytotoxic ligand may limit the number of cells that can
produce the ligand but if that ligand is in the ECM via
anchoring by DDD, the ligand may remain active and
accessible in the ECM even after death of the cell that
initially expressed it. If this type of fusion between DDD
and cytotoxic ligands results in a protein that is ﬁxed in the
ECM and signiﬁcantly active, then one can imagine
development of additional applications for the system.
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